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Apoptosis is a feature of stroke and Alzheimer’s disease (AD), yet there is no accepted method to detect or follow apoptosis in the
brain in vivo. We developed a bifunctional tracer [68Ga]Ga-TC3-OGDOTA containing a cell-penetrating peptide separated from
fluorescent Oregon Green and 68Ga-bound labels by the caspase-3 recognition peptide DEVD. We hypothesized that this design
would allow [68Ga]Ga-TC3-OGDOTA to accumulate in apoptotic cells. In vitro, Ga-TC3-OGDOTA labeled apoptotic neurons
following exposure to camptothecin, oxygen-glucose deprivation, and β-amyloid oligomers. In vivo, PET showed accumulation of
[68Ga]Ga-TC3-OGDOTA in the brain of mouse models of stroke or AD. Optical clearing revealed colocalization of [68Ga]GaTC3-OGDOTA and cleaved caspase-3 in brain cells. In stroke, [68Ga]Ga-TC3-OGDOTA accumulated in neurons in the
penumbra area, whereas in AD mice [68Ga]Ga-TC3-OGDOTA was found in single cells in the forebrain and diffusely around
amyloid plaques. In summary, this bifunctional tracer is selectively associated with apoptotic cells in vitro and in vivo in brain
disease models and represents a novel tool for apoptosis detection that can be used in neurodegenerative diseases.

1. Introduction
Neurodegenerative diseases place a devastating burden on
modern society, being among the top causes of disability and
death. One of the processes leading to neurodegeneration is
apoptosis, activated in many brain diseases, including
Alzheimer’s and Parkinson’s diseases, and in the penumbra
of an ischemic region. While there are established methods

to measure fibrillary amyloid, tau protein, and glucose
uptake by positron emission tomography (PET), and
characterize brain function by magnetic resonance imaging
[1–3], few methods have been developed to detect apoptosis
in neurological patients [4].
Apoptosis, or programmed cell death, follows either
extrinsic pathways, associated with one of the members of
the tumour necrosis factor receptor family, or intrinsic
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pathways, associated with cytochrome C release from mitochondria [5]. Both pathways eventually merge in the terminal portion of the so-called caspase cascade. This cascade
features caspase-3 activation as the ﬁnal step, triggering activation of cell content proteolysis, cytoskeleton collapse [6],
and DNA fragmentation [7]. Therefore, caspase-3 is considered a universal indicator of an apoptotic cell.
A number of caspase-3 activity markers have been developed in recent years, designed to either bind to or to be
cleaved by active/cleaved caspase-3 (CC3) at its peptide
recognition site DEVD. Highly speciﬁc CC3 inhibitors, such
as 18F-labeled isatin derivatives, were successfully employed
for PET imaging of mouse tumours [8, 9]. Synthesis of such
inhibitor-based contrast agents is widely established, but
their delivery to the brain has not been extensively documented. These reagents present some disadvantages, such as
metabolic instability, interactions with other enzymes, and
interference with apoptosis progression, since they render
CC3 inactive. Other reagents engineered to be cleaved by
CC3 to detect apoptosis inside the cell have used bioluminescence [10], ﬂuorescence resonance energy transfer,
[11] or reconstitution of a ﬂuorescent protein [12]. Among
the drawbacks of such approaches is the need to express an
exogenous protein in the system of interest and the low
tissue penetration of visible light limiting in vivo applications. Addressing this problem, compounds containing farred or near-infrared ﬂuorescent tags connected to their
quenchers through a CC3 cleavage sequence have been
designed to investigate apoptosis in vivo [13–16]. Some of
these studies have also addressed the problem of delivering
the contrast agent to the cell using various cell-penetrating
peptides (CPP) [13, 15]. While improving imaging depth,
these compounds still can be used only in cell cultures or in
close-to-surface studies of tissues such as subcutaneous
xenograft tumours in mice.
To improve imaging depth, a number of PET 18F-based
tracers have also been designed to accumulate in apoptotic
cells, due to either high aﬃnity to caspase-3 [17], removal by
CC3 of a short PEG-based cell-penetrating peptide [18, 19],
or intracellular aggregation [20]. These have been successfully applied in dexamethasone induced thymic apoptosis
[19] and cancer [18, 20].
The aim of the current study was to create a bifunctional
brain-penetrant ﬂuorescent (Oregon Green) and PETdetectable tracer molecule [68Ga]Ga-TC3-OGDOTA
designed to accumulate in vivo in cells with increased
levels of CC3 activity. We have recently shown that it is
possible to target cathepsin D in vivo in Alzheimer’s disease
(AD) using a diﬀerent tracer with a similar design [21–23].
These tracers contain an HIV1 tat-based CPP, which allows
bidirectional transport of the molecule both into and out of
cells and, thus, helps the tracer cross the blood brain barrier
and cell membranes. Inside an apoptotic cell, activated
caspases cleave the DEVD peptide, releasing the CPP and
trapping the imaging moiety inside the cell. We hypothesized that [68Ga]Ga-TC3-OGDOTA accumulation would
increase in the brain of mouse models of stroke and AD and
that [68Ga]Ga-TC3-OGDOTA would speciﬁcally label apoptotic cells.
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2. Materials and Methods
2.1. Design of the Tracer Targeting Cells with Increased CC3
Activity. To design a tracer targeting apoptotic cells, we
followed a strategy analogous to the one used in our previous
studies of a cathepsin D-targeting tracer/contrast agent
[21–24], but replacing the cathepsin D cleavage sequence
with that of CC3 (Figure 1(a)). In the resulting [68Ga]GaTC3-OGDOTA, the HIV TAT CPP is linked to a PET label,
DOTA molecule complexing 68Ga3+, and a ﬂuorescent
Oregon Green label using the CC3-cleavable peptide DEVD.
The TAT peptide allows transport of the agent into and out
of the cell. It has been shown previously that caspase-3
readily cleaves similar peptide sequences on the carboxy side
of the second aspartic acid residue [13, 15, 25]. When cleaved
within the cell cytoplasm by CC3, the CPP is free to diﬀuse
out of the cell and the non-cell-permeating ﬂuorescent and
radioactive labels are expected to be retained inside the cell
(Supplementary Figure 1(a)).
2.2. Tracer Synthesis. The PET/ﬂuorescence-labeled tracer
targeting activated (cleaved) caspase-3 [68Ga]Ga-TC3OGDOTA was prepared using the method previously
described in detail for a cathepsin D-targeted contrast
agent [21–24] by replacing the cathepsin D cleavage peptide
sequence with the DEVD peptide. Reagents were commercially available, and all solvents were HPLC or peptide
synthesis grade (Caledon Laboratories) except for water
(18.2 MΩ·cm Millipore water), and aqueous solutions were
lyophilized.
2.3. General Procedures. Oligopeptides used in this study
were assembled on a peptide synthesizer (CEM Liberty Blue)
using standard solid phase peptide synthesis (SPPS) protocols. Rink Amide MBHA resin (100–200 mesh; Peptides
International) was used as well as the protected amino acid
monomers D-tBu, E-tBu, R-Pbf, Q-Trt, K-Boc, Y-tBu, C-Trt
(N-terminal-Fmoc;
Peptides
International).
Ultraperformance liquid chromatography (Method A) was performed on a BEH C18 column (particle size 1.7 μm; 1.0 id ×
100 mm) using a chromatograph (Waters Acquity UPLC)
equipped with an autoinjector, an HR-ESI-MS detector
(Waters-Micromass, LCT Premier XT), and a photodiode
array UV detector 990M (Waters). The mobile phase was
gradient from 100% H2O to 100% MeCN (both solvents
containing 0.1% HCOOH) over 5 min, then 100% MeCN
over 2 min, with ﬂow rate of 0.1 mL/min. HPLC puriﬁcation
(Methods B and C) was performed on a Delta-Pak C18 300 Ǻ
column (particle size 15 μm; 8 × 100 mm Radial-Pak cartridge) using a chromatograph (Waters Delta 600) equipped
with an in-line ﬁlter, an autoinjector, a fraction collector,
and a photodiode array UV detector 996 (Waters). The
mobile phase for Method B was a gradient from 99% H2O/
1% MeCN to 90% H2O/10% MeCN in 10 min, then to 85%
H2O/15% MeCN in 11 min, at ﬂow rate of 3 mL/min. The
mobile phase for Method C was gradient from 90% H2O/
10% MeCN to 100% MeCN in 10 min, at ﬂow rate of 3 mL/
min. Veriﬁcation of radiolabeled conjugate purity was
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Figure 1: Ga-TC3-OGDOTA accumulates in apoptotic cells. (a) Design of [ Ga]Ga-TC3-OGDOTA. (b–f ) Ga-TC3-OGDOTA (green)
accumulation in neuronal cell cultures treated with CPT. (b) Ga-TC3-OGDOTA predominantly accumulated in cells showing apoptosis by
characteristic nuclear morphology (DAPI, blue); minor Ga-TC3-OGDOTA staining was also detected in dead cells, positive for PI (red).
Thick arrows point to apoptotic cells, arrowheads to healthy cells, and thin arrows to dead cells. (c) Quantiﬁcation of cells positive for
apoptotic nuclear morphology, Ga-TC3-OGDOTA, and PI. (d) Distribution of Ga-TC3-OGDOTA cells (OG+) within apoptotic, dead, and
healthy neurons. (e, f ) Ga-TC3-OGDOTA ﬂuorescence in cultures treated with CPT or CPT and an apoptosis inhibitor Z-DEVD-FM.
(e) Representative images for each treatment. (f ) Quantiﬁcation of Ga-TC3-OGDOTA-positive cells.

carried out by analytical radio-RP-HPLC (SunﬁreTM C18
300 Å column; particle size 15 μm; 8 × 100 mm) using a
Waters 1525 Binary HPLC pump containing a dual λ absorbance detector (Waters 2487), in-line degasser, a gamma
detector Model 105S (Carroll and Ramsey Associates), and
Breeze software (version 3.30) using a gradient from 70%
H2O/30% MeCN to 100% MeCN in 10 min, at ﬂow rate of
1 mL/min (Method D). All solvents in Methods B, C, and D
contained 0.1% TFA. Mass spectra (MS) were obtained on a
mass spectrometer (Micromass LCT Premier XT) using
electrospray ionisation. Radiolabeling was performed with
multiple runs (n � 13) on a fully automated 68Ge/68Ga
synthesizer Modular-Lab (Eckert & Ziegler). 4-(2Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buﬀer (1 M) used for radiolabeling was prepared by dissolving HEPES (23.8 g, 100 mmol) in water (100 mL), followed by adjusting the pH to 3.50 using 12 M HCl solution.

2.4. Preparation of DOTA-Peptide Conjugate for Radiolabeling.
Conjugation of 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA) terminal monomer with a peptide on the resin was carried out as described previously
(scheme 1, [24]). Crude conjugate (1) was puriﬁed by
semipreparative HPLC as described in general experimental
protocols, Method C. The pure conjugate (1) was obtained as
a triﬂuoroacetate salt from lyophilization of HPLC fractions
(9.6 mg, 5%, based on 0.05 mmol scale used for the SPPS),
colorless solid, HPLC (Method C): tR 4.2 min; HRMS (ESI)

m/z: found 2677.3674 [M+H]+ (2677.3691 calcd). Treatment
of (1) (9.6 mg, 2.3 μmol) with Oregon Green [(2), 1 mg,
2.3 μmol, Thermo Fisher] was carried out as described
previously [24]. The pure ﬂuorophore (Oregon Green)
conjugate was obtained as the triﬂuoroacetate salt (4.7 mg,
46%), red solid (Method C): tR 5.1 min; HRMS (ESI) m/z:
found 3141.4236 [M+H]+ (3141.4273 calcd).
2.5. Metallation of DOTA-Peptide Conjugate with GaCl3.
The ﬂuorophore-peptide-chelator conjugate (0.4 mg,
9 nmol) was dissolved in an acetate buﬀer (100 μL, pH 3.5),
followed by the addition of GaCl3 (Strem Chemicals) solution in water (2 mM, 90 μL). The mixture was incubated
for 20 min at 80°C; the completion of the reaction was
veriﬁed by mass spectrometry. The mixture was transferred
to a centrifuge tube, frozen and lyophilized. The residue was
used as a “cold” standard Ga-TC3-OGDOTA for radiotracer
[68Ga]Ga-TC3-OGDOTA (3) without further puriﬁcation,
HPLC (Method C): tR 2.69 min; HRMS (ESI) m/z: found
3207.3138 [M-2H]+ (3207.3294 calcd).
2.6. Preparation of Radiolabeled Conjugate [68Ga]Ga-TC3OGDOTA. Oregon Green conjugate (0.03 mg, 6.7 nmol, (2)
on Scheme 1) was dissolved in water (55 μL) and added to
700 μL, 1 M HEPES, pH 3.5, in a sterile vial (Scheme 1).
Radiolabeling was performed as described in General procedures. A solution of [68Ga]GaCl3 in 0.1 M HCl was eluted
into the vial to reach the activity 219.2 ± 22.1 MBq. The vial
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Scheme 1: Preparation of radiolabeled probe [68Ga]3 � [68Ga]Ga-TC3-OGDOTA.

was incubated for 10 min at 100°C, followed by solid phase
extraction on a Waters light tC18 Sep-pak cartridge, consecutively eluting with water (2 mL) and EtOH (2.5 mL). The
radiolabeled peptide ([68Ga]3, Scheme 1) was obtained as a
solution in EtOH (in a sterile vial), the activity of the peptide
solution was 41.7 ± 10.1 MBq, radiochemical yield (decay
corrected after 15 min, 10 min synthesis +5 min drying) 19 ±
4%, molar activity 6.22 ± 1.51 GBq/μmol. EtOH was removed
by a stream of N2 at 80°C; the residue was subsequently used
for the animal studies. The purity of radiotracer (3) was
veriﬁed by HPLC (Method C, tR 2.58 min), by comparison
with the chromatograms corresponding to the “cold” standard described above (Supplementary Figure 1(b)). The absence of colloidal 68Ga was ensured by the solid phase
extraction step as described elsewhere [26] and supported by
nonaugmented tracer uptake (Supplementary Figure 3(b)) in
liver (0.78% ID/g) and bone marrow (hip, 0.07% ID/g).
2.7. In Vitro Validation: Primary Neuronal Cultures. For the
in vitro cell culture studies, primary hippocampal and
cortical neuronal cultures were prepared from E17 mouse

embryos as described previously [27] and cultured in regular
neuronal medium (RNM) containing 1x B27, 0.5 mM glutamine, 0.25% glucose in Neurobasal medium (Invitrogen).
Both male and female embryos were used for cultures as the
toxicity conditions used in this study have not been shown to
depend on sex diﬀerences.
Three diﬀerent conditions known to induce neuronal
apoptosis were used to study Ga-TC3-OGDOTA uptake in
cell culture: camptothecin (CPT) toxicity, OGD, and AβO
toxicity. These assays model diﬀerent conditions that may
occur in vivo and demonstrate the versatility of the tracer.
For the CPT toxicity assay, cortical neurons were treated
with 0 (control) or 10 μM CPT (Sigma-Aldrich) for 24 h at
normal conditions (5% CO2, 37°C). After that the cultures
were washed with RNM and incubated with various concentrations of Ga-TC3-OGDOTA for 7 h, followed by either
direct live imaging or ﬁxation with 4% paraformaldehyde
(PFA) in PBS for staining.
For OGD studies, the media in the hippocampal neuronal cultures on day 7 were saved and replaced with RNM
without glucose. Cells were incubated for 1 h at 37°C in 95%
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N2/5% CO2 atmosphere with less than 0.2% O2 as described
previously [28]. For control experiments, cells were incubated for the same time under normal conditions. 1-hour
OGD was followed by 7-hour reperfusion in the saved media
supplemented with 3 µM Ga-TC3-OGDOTA under normal
conditions. After that, cultures were either imaged live directly or ﬁxed with 4% PFA for staining.
For the AβO toxicity assay, AβOs were prepared from
Aβ (1–42) monomer (rPeptide, cat#A-1002-2) as described
previously [27]. The quality of the AβO preparations
was checked by Western blotting as described previously
[27], using Bolt 4–12% precast gels (Thermo Fisher,
cat#NW04120BOX). 1 µM AβOs (or vehicle for controls)
was added to hippocampal neuronal cultures on day 11. The
amount of toxic trimers and tetramers of Aβ estimated by
Western blotting was ∼10–20 nM [27]. This is within the
range found to be toxic in other studies using synthetic [29]
or AD brain-puriﬁed [30] AβOs. Cell cultures were incubated for 24 h, and 3 µM Ga-TC3-OGDOTA was added
for the last 7 h. After that, cultures were either imaged live
directly or ﬁxed with 4% PFA for staining.
For live imaging of Oregon Green, cultures were washed
3x with Krebs-Ringer HEPES (KRH) buﬀer and imaged
using an FV1000 confocal microscope (Olympus) equipped
with a 20x/0.75 lens with excitation at 488 nm and emission
at 505–550 nm.
For coimaging of Hoechst 33342 (Hoechst), 4′,6′Diamidino-2-Phenylindole (DAPI), Oregon Green and
CC3, ﬁxed cultures were immunostained with anti-CC3
antibody (1 : 500, Cell Signaling, cat#9661) followed by
antirabbit secondary antibody and DAPI or Hoechst. After
that, cultures were mounted on slides and imaged using an
FV1000 confocal microscope (Olympus) equipped with a
20x/0.75 objective. Cells positive for tracer, CC3, and total
number of cells were counted using the ImageJ (NIH,
Bethesda, MD) Cell Counter plugin and their ratio was
compared between the treatments.
Cell viability was assessed using the ImageJ Cell Counter
plugin. Speciﬁcally, the toxicity of the agent was calculated as
the percentage of nuclei showing characteristics of dead cells
in Hoechst or DAPI stained sections.
2.8. In Vivo and Ex Vivo Validation: Middle Cerebral Artery
Occlusion (MCAO) and AD Mouse Models. For in vivo
validation of tracer uptake and colocalization with CC3, we
used mouse models of MCAO and AD. All procedures were
conducted in accordance with the guidelines of the Canadian Council of Animal Care and approved by the University
of Western Ontario Animal Use Subcommittee (protocol
2016–103 and 2016–104). The study also complied with the
ARRIVE guidelines (Animal Research: Reporting in Vivo
Experiments). To test whether [68Ga]Ga-TC3-OGDOTA
could detect brain injury/apoptosis in vivo, we employed
a widely used model of stroke, MCAO. During this procedure, blood ﬂow is blocked resulting in ischemic injury
predominantly in the striatum and cortex, which during the
ensuing reperfusion/recovery period can also aﬀect adjacent
brain regions [31, 32] (Supplementary Figure 3(a)). MCAO
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is characterized by an extensive core, or edema, consisting of
massive necrotic tissue, and by a penumbra, which is present
at the periphery of the core and is characterized by abundant
apoptosis [33]. MCAO was performed as previously described [28] in 3–4 month old wild-type male mice (weight,
average ± SD: 28 ± 2 g) in either C57BL/6J or B6SJL
background. Brieﬂy, isoﬂurane-anaesthetized mice were
immobilized under the operating microscope, and a 0.06–
0.09 mm nylon suture was inserted via the left carotid artery
into the internal carotid artery and then into the circle of
Willis to occlude the MCA. Sham-operated mice were
subject to the same procedure except for the suture-induced
occlusion. Mice were then removed from anaesthesia and
kept under a heat lamp for 60 min, after which they were
anaesthetized again and the suture was removed. Operated
mice were held in a cage with a heated pad for 24 h, receiving
1 mL saline injections i.p. every 12 h. Neurological state was
assessed using the 5-point Bederson scale and only mice
scoring 2 (severe forelimb weakness, consistent turns to the
deﬁcit side when lifted by the tail) or 3 (compulsory circling)
were used for the experiments. MCAO eﬃciency was estimated by triphenyl tetrazolium chloride (TTC) staining.
After 24 h of reperfusion, the animals were euthanized.
Brains were frozen at –80°C for 15 min and sliced into 1 mm
coronal sections. The brain slices were immersed in the 2%
TTC solution for 15 min at 37°C, washed with 0.9% saline
solution, and imaged by a digital camera. The ischemic
damage to coronal brain sections was qualiﬁed by the absence of staining.
In AD, neurodegeneration eventually leads to the
shrinkage of the hippocampus and cortex, but in vitro and ex
vivo experiments suggest that neuronal apoptosis can start as
early as the accumulation of Aβ [34, 35]. Neurodegeneration
is not frequently observed in mouse models of AD, and the
5xFAD model is one of the few AD mouse models that
present this AD hallmark [36]. Neurodegeneration, including neuronal loss, and increased caspase-3 activity were
shown to manifest by the age of 8–9 months; therefore, we
used 5xFAD mice older than 8 months to test [68Ga]GaTC3-OGDOTA. 5xFAD mice in B6SJL background (B6SJLTg(APPSwFlLon, PSEN1∗M146L∗L286V)6799Vas/J) were
purchased from Jackson Laboratories (Bar Harbor, ME) and
cross-bred with wild-type B6SJL mice in our facility. Both
male (weight, average ± SD: wild-type- 34 ± 7 g, transgenic32 ± 4 g) and female (weight, average ± SD: wild-type- 29 ±
7 g, transgenic- 22 ± 3 g) littermates were used for the experiments. A summary of animals used for this work is
provided in Table 1.
2.9. Positron Emission Tomography (PET) in Mice.
Imaging was performed as described previously for the
cathepsin D tracer [22], using list mode scanning on the
Inveon preclinical PET system (Siemens). PET scanning and
data analysis using the CARIMAS software (Turku PET
centre, Finland) were performed following the standard
procedures. All mice received a slow intravenous injection of
11.2 ± 1.0 MBq [68Ga]Ga-TC3-OGDOTA suspended in
∼150 µL saline through a tail vein catheter. To reduce
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Table 1: Summary of the animal use.
Condition/
genotype

Stroke
model
AD
model
∗

MCAO
Sham-operated
controls
5xFAD
WT controls

Sex

Mice injected with [68Ga]GaTC3-OGDOTA
PET

Subset used
Thin
CLARITY Unused
sections
4
3
1∗

Mice used for
TTC staining

Total number
of mice

2

10

m

8

5

m

6

3

3

3

0

—

6

m
f
m
f

3
7
3
6

3
7
3
6

0
0
0
0

3
3
1
1

0
0
0
0

—
—
—
—

3
7
3
6

Died during anaesthesia.

discomfort, the solution was adjusted to a nearly neutral
pH using dropwise dilutions of HCL/NaOH and litmus
paper prior to administration. Imaging was initiated
∼1 min before injection of the tracer and lasted for 2 h.
Histograms were built using dynamic step intervals set to 5
× 30 s at the beginning of the imaging, followed by 5 × 60 s,
5 × 300 s, and 600 s steps for the remaining time. Acquisition (energy window 350–650 keV, timing window
3.432 ns), histograms, and reconstructions were performed using the Siemens Inveon software supplied with
the scanner. Histograms were built using separate delay
handling, global deadtime correction, and 79 ring diﬀerence for maximum sensitivity. For reconstruction, the
Ordered-Subsets Expectation Maximization (OSEM3D)
with ordinary Poisson Maximum a posteriori OP-MAP (2
OSEM3D iterations, 18 MAP iterations) algorithm was
used. The resulting 3D data set had a matrix of 128 × 128 ×
159 and a voxel size of 0.78 × 0.78 × 0.80 mm in the x-, y-,
and z-directions. Attenuation correction was not performed as the mouse head size does not justify the use of
such a correction and does not vary much between animals. Animals were kept warm (∼37°C) using a ﬂoor
mounted heating lamp before, during, and immediately
after the imaging session with body temperature monitored by rectal probe. For scanning, mice were anaesthetized with isoﬂuorane (<1.5%). For brain ﬂuorescence
imaging following MCAO, mice were kept on the heating
pad until their euthanasia. Mice were studied at 34 months (MCAO, N � 5; sham N � 3), ∼8.5 months (male:
5xFAD, N � 3; wild type, N � 3), and 11 months (female:
5xFAD, N � 7; wild type, N � 6) of age.
2.10. PET Data Analysis. The pattern of tracer uptake and
washout from brain and other mouse organs (Supplementary Figure 3(b)) was as expected with a rapid increase
followed by a gradual washout from the brain. Analysis of
the linear decay of the PET signal kinetics as well as Patlak
graphical analysis were used to study [68Ga]Ga-TC3OGDOTA uptake in mouse brains. Region of interest
(ROI) assignment and Patlak graphical analysis [37, 38] of
the time-activity curves (TACs) derived from these ROIs
were performed using the CARIMAS software (Turku PET
centre, Finland) using the embedded Patlak function. As a
reference region, the left ventricle was used in the stroke

mouse model and the hindbrain in the AD mouse model.
PET signals from the [68Ga]Ga-TC3-OGDOTA injected into
MCAO and sham-operated mice were analyzed by comparing operated (ipsilateral) vs. nonoperated (contralateral)
sides of forebrain. We assumed that in an MCAO brain, the
ipsilateral ROI would contain most of the MCAO-induced
damaged tissue, while the contralateral ROI would contain
healthy tissue (Figure 2(a)). We normalized PET signal in
AD-aﬀected forebrain with that in hindbrain (Figure 3(a)), a
brain region that exhibits signiﬁcantly lower beta-amyloid
production [39] and accumulation [22] and has been successfully used as a control ROI in previous PET studies of
5xFAD mice [22, 40]. To facilitate ROI assignment and
distinguish brain from surrounding tissue, the integrated
PET signal was manually aligned with a computed tomography (CT) image of a mouse of the same genetic background and similar weight, as described previously [22]. The
CT examination used for visual guidance of anatomical
landmarks was performed with the Revolution CT (GE
HealthCare Ltd.) human scanner using a helical scan of 120
kVp with a 1.25 mm slice thickness and a 0.2 × 0.2 mm inplane resolution. Representative Patlak Ki maps for each
condition or genotype were prepared by the CARIMASembedded image ﬁlter function and manually aligned with a
mouse CT image. ROI-derived TACs were also exported into
GraphPad Prism 6.0 software and compared using 2-way
analysis of variance (ANOVA) and linear approximation.
2.11. Confocal Microscopy on 20 µm Brain Sections. 20 h
after [68Ga]Ga-TC3-OGDOTA injection, mice were
anaesthetized and transcardially perfused with PBS followed
by 4% PFA in PBS as described previously [41]. Immunohistochemistry on brain sections was performed as described
previously [42], using rabbit anti-CC3 antibody (1 : 500),
antirabbit Alexa633 secondary antibody, and Hoechst
33342. Sections were imaged with an FV1000 confocal
microscope equipped with 10x/0.4 and 20x/0.75 objectives.
Obtained images were analyzed using ImageJ.
2.12. Optical Clearing of Hydrogel-Embedded Mouse Brains.
For confocal imaging of 2 mm brain sections mice were
anaesthetized 20 h after [68Ga]Ga-TC3-OGDOTA injection,
placed on ice and transcardially perfused with hydrogel
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Figure 2: PET kinetics of [ Ga]Ga-TC3-OGDOTA retention in MCAO and sham-operated mouse brains. (a) Scheme of ROIs for PET
signal integration over the left (occluded) and right (nonoccluded) brain halves. (b–i) PET signal kinetics and their analyses in MCAO
and sham-operated brains. (b) Sample PET kinetics in MCAO brain halves showing linear approximation during the 2nd hour of signal
acquisition. (c) The same for sham-operated brains. (d, e, h) Comparison of linear approximation slope (d) and graphic analysis Patlak
constants (e) for MCAO brains. (h) Representative coronal and axial sections of Ki mapping in an MCAO mouse brain. Ki map was
aligned with a CT mouse image manually as described in Methods. (f, g, i) The same as (d, e, h) but for sham-operated brains. Data were
collected from 5 MCAO and 3 sham-operated mice.

monomer solution (4% PFA, 4% acrylamide, 0.05% bisacrylamide, 1 g/L VA-044 (Wako Chemicals USA, VA) in
PBS) as described for the CLARITY procedure [43]. After
48-hour gel polymerization the brains were cut with VT1200
vibratome (Leica) into 2 mm sections, which were then
cleared under constant ﬂow of 4% SDS in 0.2 M sodium
borate, pH 8.5, for 72–96 h. In order to visualize the sites of
accumulation of [68Ga]Ga-TC3-OGDOTA in the AD mouse
model, we used optical clearing of [68Ga]Ga-TC3OGDOTA-injected 5xFAD and control brains.
2.13. Confocal Microscopy on 2 mm Thick Mouse Brain
Sections. Optically cleared sections were placed into SeeDB

mounting medium (80.5% w/w D-fructose, 0.5% thioglycerol, [44]) and imaged using an FV1000 confocal microscope equipped with air 10x/0.4, 20x/0.75, or silicon oil
30x/1.05 objectives.
For CC3 imaging, the tissue was incubated with antiCC3 antibody (1 : 50) in PBS-Tfor 5 days at 37°C, followed by
washing with PBS-T 3 × 12 h, incubation with anti-rabbit
Alexa Fluor 633 secondary antibody (1 : 50) in PBS-T for
3 days at 37°C and washing with PBS-T 3 × 12 h. After that,
the sections were imaged in SeeDB mounting medium using
the same excitation/emission parameters as for thin brain
sections. 3D reconstruction and image analysis were performed using ImageJ 3D stack module.
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Figure 3: PET kinetics of [ Ga]Ga-TC3-OGDOTA retention in 5xFAD mouse brains and wild-type controls. (a) Scheme of ROIs for PET
signal integration over the forebrain (fb) and hindbrain (hb, control area). (b–h) Relative (fb/hb) PET signal kinetics and their analyses in
5xFAD mouse brains compared to wild-type controls. (b) Relative PET kinetics in 5xFAD and control 8-month-old male brains were
linearly approximated starting from ∼10 min timepoint. (c) Comparison of Patlak Ki for (b) kinetics. (d) Representative coronal and axial
sections of Ki mapping in a wild-type (WT, left) and a 5xFAD (right) mouse brains. The Ki map was aligned with a CTmouse image manually
as described in Methods. (e, g) Relative PET kinetics in 5xFAD and control male (e) and female (g) brains were linearly approximated
starting from ∼10 min timepoint. (f ) Comparison of Patlak Ki for (e) kinetics. (h) Comparison of Patlak Ki for (g) kinetics.
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2.14. Statistics. For statistical analysis of ﬂuorescence, Student’s t-tests (paired or unpaired, when needed) were performed using GraphPad Prism 6 software. For statistical
analysis of PET kinetics, linear approximation, Student’s ttest, and 2-way ANOVA were performed using GraphPad
Prism 6, and Patlak analysis [37] was performed using the
CARIMAS software. Power and sample size analysis based on
the PET data obtained in this study was performed using the
Matlab function “sampsizepwr” (https://www.mathworks.
com/help/stats/sampsizepwr.html, MathWorks).

3. Results
3.1. Ga-TC3-OGDOTA Accumulates in the CPT Cell Culture
Model. Treatment of primary cortical cultures with the
DNA topoisomerase I inhibitor CPT, shown previously to
induce neuronal apoptosis [45], elevated the number of
apoptotic neurons in the culture (Supplementary
Figures 2(a) and 2(b)). When Ga-TC3-OGDOTA was added
to CPT-treated cultures, it accumulated predominantly
(88%) in the cells showing characteristic apoptotic nuclear
morphology, with only minor nonspeciﬁc staining of the
dish surface and dead cells (Figures 1(b)–1(d)). This increase
in Ga-TC3-OGDOTA-positive cells was prevented when
neuronal cultures were cotreated with CPT and the CC3
inhibitor Z-DEVD-FM (Figures 1(e) and 1(f )), which also
decreased apoptosis-related changes in nuclear morphology.
3.2. TC3-OGDOTA Accumulates in Stroke and AD Cell
Culture Models. Analysis of the OGD-treated ischemic
cultures showed an increased number of neurons that were
both positive for CC3 and apoptosis-related changes in
nuclear morphology, as detected by the Hoechst ﬂuorescent
dye (Supplementary Figure 2(c)). When added to the media
during post-OGD incubation under normal conditions,
Ga-TC3-OGDOTA accumulated in 40% of neurons, compared to only ∼5% accumulation in nonischemic controls
(Figures 4(a) and 4(b)). As with CPT treatment, intracellular localization of Ga-TC3-OGDOTA was ubiquitous
throughout the cell (Figure 4(a)). Immunostaining of these
cultures for CC3 revealed a very similar increase in the
proportion of cells positive for Ga-TC3-OGDOTA and CC3
under both OGD and control conditions (Figures 4(c) and
4(d)). Notably, almost all (91%) of the cells positive for either
Ga-TC3-OGDOTA or CC3 had both markers present. Intracellular localization of Ga-TC3-OGDOTA after immunostaining diﬀered to some extent from that in live cultures,
probably due to ﬁxation and partial washout.
24-hour AβO treatment induced signiﬁcant apoptosis in
neurons (Supplementary Figure 2(d)) and ﬂuorescence
imaging in live cultures revealed an increase in Ga-TC3OGDOTA-positive neurons, similar to that observed with
CPT and OGD treatments (Figures 4(e) and 4(f )). Moreover,
Ga-TC3-OGDOTA was seen predominantly (∼90%) in
neurons presenting CC3 staining and apoptotic nuclear
morphology (Figures 4(g) and 4(h)), similar to the OGD
experiment. In ﬁxed OGD and AβO-treated cultures, GaTC3-OGDOTA was distributed ubiquitously in some cells,
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similarly to the pattern observed in live cultures. At the same
time in other cells, the tracer appeared to have a
compartment/aggregate-like localization (Figures 4(c) and
4(g)). While Ga-TC3-OGDOTA and CC3 immunoreactivity
were generally colocalized within a cell (Figures 4(c) and
4(g)), some cells exhibited preference towards one or the
other dye (Figure 4(g), bottom panel).
It is noteworthy that in both neuronal culture models of
apoptosis, Ga-TC3-OGDOTA was not cytotoxic at the
concentrations studied. In control cultures incubated with
Ga-TC3-OGDOTA, 17 ± 1% of cells showed evidence of
neuronal damage, which was similar to that observed in
control cultures without Ga-TC3-OGDOTA (16 ± 2%). This
observation corroborates our previous experiments with a
similar compound using TAT [23].
3.3. PET Detects [68Ga]Ga-TC3-OGDOTA Retained by Ischemic Brains in Mice. After the initial exponential drop, the
PET signal showed almost linear kinetics starting at ∼50 min
(Figures 2(b) and 2(c)). In the MCAO brains, the PET signal
decayed more slowly on the ipsilateral side compared to the
contralateral, suggesting accumulation of [68Ga]Ga-TC3OGDOTA in the ischemic tissue (Figure 2(b)). Lateralized
diﬀerences in PET signal dynamics were not observed in
sham-operated controls (Figure 2(c)). Indeed, the linear approximation of the second hour of the kinetics showed signiﬁcantly lower decay constant on the occluded side, but only
in MCAO brains (Figures 2(d) and 2(f)). We also employed
Patlak graphical analysis [37, 38], which can show irreversible
binding of the ligand in the selected region. We used the heart
as the reference region representing zero retention (http://
www.turkupetcentre.net/petanalysis/model_reference_tissue.
html). In MCAO (Figures 2(e) and 2(h)), but not shamoperated (Figures 2(g) and 2(i)) mice the retention constant
(Ki) on the side ipsilateral to the surgery side of the forebrain
was positive (p � 0.004), suggesting [68Ga]Ga-TC3-OGDOTA
accumulation in MCAO, but not in sham-operated brains.
Interestingly, in MCAO brains, Ki was generally positive even
on the contralateral side (p � 0.042, Figure 2(e)), with a
tendency to be smaller than on the ipsilateral side (p � 0.090).
This result suggests that the side contralateral to MCAO may
also have accumulated [68Ga]Ga-TC3-OGDOTA. It is possible
that brain damage in some cases might have spread into the
contralateral half of the brain, which has been observed previously in MCAO mouse models [46, 47]. Variations in the
severity of the injury lead to poor deﬁnition of the ROI, which
together with changes in cerebral blood circulation in the
infarct and penumbra areas could explain the failure to distinguish ipsilateral and contralateral sides by Patlak analysis.
3.4. Cells on the Ischemic Side Display [68Ga]Ga-TC3OGDOTA Fluorescence. Imaging of thin coronal slices of
mouse brains perfused and ﬁxed 20 h after [68Ga]Ga-TC3OGDOTA injection showed signiﬁcantly higher ﬂuorescence on the ischemic side in the MCAO brains compared to
the contralateral side and of both sides in sham-operated
controls (Figures 5(a) and 5(b)). While the Oregon Green
ﬂuorescence was detected throughout the ipsilateral side, it
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Figure 4: Ga-TC3-OGDOTA accumulates in apoptotic neurons in vitro in ischemia and AD cell culture models. (a–d) Ga-TC3-OGDOTA
accumulation in primary neurons treated with OGD was analyzed in live cultures (a, b) and in ﬁxed cultures costained for nuclei (Hoechst)
and CC3 (c, d). (a) Representative images of live OGD-treated and control cultures. (b) Quantiﬁcation of Ga-TC3-OGDOTA-positive
(OG+) live cells in OGD/control cultures. (c) Representative images of ﬁxed/immunostained control (top-left), OGD (top-right), and OGD
zoomed (bottom) cultures. (d) Quantiﬁcation of Ga-TC3-OGDOTA-positive (OG+) and CC3-positive cells in ﬁxed OGD/control cultures.
(e–h) Ga-TC3-OGDOTA accumulation in primary neurons treated with AβOs was analyzed in live cultures (e, f ) and in ﬁxed cultures
costained for nuclei (Hoechst) and CC3 (g, h). (e) Representative images of live AβO-treated and control cultures. (f ) Quantiﬁcation of GaTC3-OGDOTA-positive (OG+) live cells. (g) Representative images of ﬁxed control (top-left), AβO (top-right), and AβO zoomed (bottom)
cultures. (h) Quantiﬁcation of Ga-TC3-OGDOTA-positive (OG+) and CC3-positive cells in ﬁxed AβO/control cultures. Cells presenting
high levels of both Ga-TC3-OGDOTA and CC3 are marked with white arrows, while those with preferential Ga-TC3-OGDOTA or CC3
accumulation are marked with green or red arrows, respectively. Data were collected from at least 3 independent cultures for each condition
and analyzed with Student’s t-test or Two-way ANOVA. ∗ p < 0.05; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.

was more intense in the periphery than in the injury core,
suggesting that [68Ga]Ga-TC3-OGDOTA is retained more
in the penumbral area compared to the infarct core. Morphological analysis showed that ﬂuorescent objects were
mostly single cells and small blood vessels (Figures 5(a) and

5(b), Supplementary Figure 3(c)). In addition, some sections
displayed weak and diﬀuse ﬂuorescence in the cortex, which
probably reﬂected autoﬂuorescence, as a similar pattern was
observed in the MCAO brains that were not injected with
[68Ga]Ga-TC3-OGDOTA (Supplementary Figure 3(c)).
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Figure 5: Fluorescence microscopy in brains extracted from [ Ga]Ga-TC3-OGDOTA-injected MCAO and sham-operated mice. (a, b) [68Ga]GaTC3-OGDOTA ﬂuorescence in 20-µm coronal brain sections. (a) Representative images of MCAO (top left and right panels) and sham-operated
(bottom left panel) brains. (b) Quantiﬁcation of ﬂuorescence integrated over the left (operated) vs. right (nonoperated) brain halves. Data were
averaged over 4 sections for each brain collected from 4 MCAO and 3 sham-operated mice and analyzed by Student’s t-test. (c, d) Sections of the
same brains immunostained for CC3 (red) and Hoechst (blue). [68Ga]Ga-TC3-OGDOTA presence was probed in Oregon Green channel (OG,
green). (c) Representative images of MCAO (top left and right panels) and sham-operated (bottom left panel) brains. (d) Quantiﬁcation of CC3positive cells in the left (operated) vs. right (nonoperated) brain halves. Data were averaged over 4 sections collected from 3 brains for each
condition and analyzed by two-way ANOVA followed by Bonferoni post hoc test. ∗ p < 0.05; ∗∗ p < 0.01 (E-G) [68Ga]Ga-TC3-OGDOTA
ﬂuorescence (OG, green) in optically cleared 2 mm brains sections. (e) Representative images of 1 mm z-stack images of coronal sections of MCAO
(top) and sham-operated (bottom) brains. (f, g) Representative images of the MCAO brain sections immunostained for CC3 and imaged for both
[68Ga]Ga-TC3-OGDOTA and CC3 (red). Cells positive for both [68Ga]Ga-TC3-OGDOTA and CC3 are marked with white arrows, blood
vessels—with red arrows. (f) Thalamus, 20x objective, ipsilateral side. (g) Cortex (top) and thalamus (bottom), 60x objective, ipsilateral side.

3.5. CLARITY Imaging Shows That [68Ga]Ga-TC3-OGDOTA
Colocalizes with CC3 in Cells. CC3 immunostaining of thin
sections showed a preferential staining of the MCAOoperated side compared to the contralateral side and
sham-operated controls (Figures 5(c) and 5(d)). In these
sections, [68Ga]Ga-TC3-OGDOTA ﬂuorescence was faded,
and we could not detect signiﬁcant colocalization of [68Ga]
Ga-TC3-OGDOTA and CC3, probably, due to detergentinduced washout.
In order to bypass this limitation of immunostaining, we
employed CLARITY, shown to maintain protein content
while facilitating tissue penetration by antibodies and
allowing imaging with millimeter-range depth [43]. First, we
conﬁrmed that extensive washing with 4% SDS buﬀer did not

remove [68Ga]Ga-TC3-OGDOTA from hydrogen-embedded
cells (Supplementary Figure 3(d)). Cleared brain sections
(Supplementary Figure 3(e)) showed a ﬂuorescence pattern
similar to that detected in thin sections (Figure 5(e)). The
ischemic side of the brain presented higher ﬂuorescence
intensity compared to the contralateral side and the shamoperated controls (Figure 5(e)), observed predominantly in
the penumbral area, including cortex (Supplementary Video
1) and midbrain (Supplementary Video 2) regions. Distribution of the immunostained CC3 in these sections was
similar to that of [68Ga]Ga-TC3-OGDOTA, with major CC3
localization in cortex (Supplementary Video 3) and midbrain
(Supplementary Video 4). Cells positive for both [68Ga]GaTC3-OGDOTA and CC3 were abundant throughout these
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regions though a number of cells contained only one of these
markers (Figures 5(f) and 5(g)), which may indicate various
stages of apoptosis in those cells.
3.6. PET Detects [68Ga]Ga-TC3-OGDOTA Accumulation in
the Forebrain of 5xFAD Mice. PET normalized signal did not
diﬀer signiﬁcantly between 5xFAD mice and wild-type mice,
but its attenuation at 10–110 min after injection was negative
in 5xFAD mice, but not in wild-type mice (Figure 3(b)). This
result suggests that [68Ga]Ga-TC3-OGDOTA accumulated
in 5xFAD forebrain relative to hindbrain. The Patlak
graphical analysis on the kinetics using hindbrain as the
reference region supported this argument showing a positive
Patlak Ki constant for 5xFAD, but not wild-type mice
(Figures 3(c) and 3(d)). We also separated mice into two
groups, males (N � 3 for each genotype) and females (N�6
for wild-type, N � 7 for 5xFAD). Both male (Figures 3(e) and
3(f )) and female (Figures 3(g) and 3(h)) mice showed increased [68Ga]Ga-TC3-OGDOTA accumulation via the
decay and the Patlak Ki constant, compared to their wildtype littermates, although with less power due to the lower N
values.
3.7. CLARITY Reveals [68Ga]Ga-TC3-OGDOTA Accumulation in 5xFAD Forebrain. Confocal imaging showed signiﬁcantly higher levels of ﬂuorescence in 5xFAD brains
compared to wild-type controls (Figure 6(a), Supplementary
Video 5). Higher magniﬁcation images detected ﬂuorescence coming from both cells and around amyloid plaquelike structures (Figure 6(b), Supplementary Video 6). Indeed, staining with Thioﬂavin S showed signiﬁcant colocalization with [68Ga]Ga-TC3-OGDOTA throughout the
5xFAD forebrain (Figures 6(c) and 6(d), Supplementary
Videos 7 and 8, Thioﬂavin S(blue), [68Ga]Ga-TC3OGDOTA (yellow)), though [68Ga]Ga-TC3-OGDOTA
was found more on the periphery of plaques.

4. Discussion
In this study, we designed a tracer molecule for PET and
ﬂuorescence imaging aimed at identifying cells with increased CC3 activity. We observed in both in vitro and in
vivo experiments that its accumulation is directly linked to
increased apoptosis. [68Ga]Ga-TC3-OGDOTA was detected
in cells showing increased levels of CC3 and apoptosisassociated nuclear morphology. In injured brain tissue, it
marked the areas previously associated with increased apoptosis such as penumbra in stroke, and cortex and hippocampus in a model of AD. Previous ﬁndings, in vitro or ex
vivo, showed that ischemic insult [33, 48] or the presence of
beta-amyloid oligomers [49, 50] led to apoptotic neuronal
death. Similarly, we have shown that these insults signiﬁcantly increased the number of neurons positive for CC3, a
common marker of apoptosis, and that [68Ga]Ga-TC3OGDOTA accumulation follows the same pattern and
signiﬁcantly overlaps with CC3 immunostaining. For these
experiments, we used both traditional confocal microscopy
on 2D cultures and thin (20-µm) brain sections, and deep-
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tissue (up to 1 mm) confocal imaging on SDS-cleared
hydrogel-embedded 2-mm brain sections. One of the advantages of the latter method is the cross-linking of [68Ga]
Ga-TC3-OGDOTA amino-groups with the hydrogel mesh,
which helps to preserve the tracer in the cells during the
clearing/washing steps. Thus, hydrogel-embedding allowed
for [68Ga]Ga-TC3-OGDOTA coimaging with CC3. Besides,
deep-tissue imaging covers a signiﬁcant portion, if not the
whole tissue of interest, and, therefore, is less prone to error.
The current study further advances the imaging of apoptosis in disease. Recently, far-red/near-infrared contrast
agents speciﬁc to CC3 activity were used in vivo [13, 15] that
showed facilitation of the agent delivery into the cell by
HIV1 Tat-based CPPs. We also used such CPPs in a tracer/
contrast agent targeting cathepsin D, and showed its retention in the 5xFAD forebrain in vivo using PET [22], nearinfrared ﬂuorescence [21], and MRI labels [23]. Of note, its
accumulation in cells depended on the CPP, justifying the
necessity of the CPP presence in the CA structure. Recently,
PET 18F-labeled tracers, also based on the DEVD peptide
have been developed [19, 20]. Future studies should compare
the blood-brain barrier penetration eﬃciency of these agents
to our bifunctional tracer.
It is worth noting that in cultured neurons while both
Ga-TC3-OGDOTA and anti-CC3 antibody were present in
most apoptotic cells, their intensities and subcellular localization diﬀered in some of these cells (Figure 4). One
possible explanation is a delayed eﬀect of the tracer accumulation. Indeed, the substrate cleavage product is expected
to peak with a delay relative to the enzyme activity peak.
Regarding diﬀerences in subcellular distribution of CC3 and
the tracer, diﬀerence in diﬀusion speed between a small
tracer molecule and a large protein molecule, and caspase
translocation between compartments during the progress of
apoptosis must be considered. It is also possible that at this
stage, the tracer had to compete with other abundant CC3
substrates, such as procaspases.
While Ga-TC3-OGDOTA/[68Ga]Ga-TC3-OGDOTA
clearly accumulated in apoptotic cells in primary neuronal cultures and in brain tissues of two mouse models of
increased apoptosis, we observed some additional, possibly
nonspeciﬁc, ﬂuorescent objects in both cases. Some of these
objects originated from brain tissue autoﬂuorescence and
were detected in both conventional 20-µm brain sections
and CLARITY-treated 2-mm brain sections (Figure 5,
Supplementary Figure 2). These autoﬂuorescent objects may
result in false positive results, when no additional immunostaining is performed. However, most often they have
non-cell-like morphology (blood vessels, diﬀused ﬂuorescence) and, therefore, can easily be distinguished from
[68Ga]Ga-TC3-OGDOTA-positive cells. In cell cultures, GaTC3-OGDOTA bound to dead cell debris (Figure 1), which
can be distinguished from apoptotic cells by propidium
iodide staining, which could be explained by caspase-3
translocation to the nucleus [51]. In 5xFAD brains, [68Ga]
Ga-TC3-OGDOTA accumulated in well-deﬁned cells, but
also abundantly surrounded amyloid plaques and may help
in their visualization. These events may suggest some
nonspeciﬁc interaction between [68Ga]Ga-TC3-OGDOTA
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Figure 6: Fluorescence microscopy in optically cleared brains extracted from [ Ga]Ga-TC3-OGDOTA-injected 5xFAD and wild-type
mice. (a) [68Ga]Ga-TC3-OGDOTA ﬂuorescence (green) in optically cleared 2-mm wild-type (top) and 5xFAD (bottom) brain sections. The
sections were imaged with 1 mm depth and 3D reconstruction was prepared using ImageJ as described in Methods. (b) [68Ga]Ga-TC3OGDOTA ﬂuorescence in the hippocampus of 5xFAD brains. A coronal section was imaged with 0.3 mm depth and 3D-reconstructed. (c, d)
Sections from (a) were stained for amyloid plaques with thioﬂavin S. (c) Hippocampi of wild-type (top) and 5xFAD (bottom) were imaged
for plaques (ThioS, blue) and [68Ga]Ga-TC3-OGDOTA (OG, yellow). (d) Confocal images of 5xFAD brains showing amyloid plaques
(white arrows) surrounded by [68Ga]Ga-TC3-OGDOTA-positive objects.

and native molecules, which could be aided by ionic interactions between the positively charged cell-penetrating
peptide of the tracer and the net negative charge of Aβ or
DNA. Such interactions have been shown for other proteins
with similar peptide sequences, such as the cellular prion
protein. Its N-terminal domain contains motifs similar to
those of the CPP and binds Aβ with nanomolar aﬃnity [27]
as well as DNA and RNA [52, 53]. Due to their lower
speciﬁcity and/or spatial/morphological features, the identity of such interactions should be readily distinguishable
from the desired signal. However, further studies are needed
to conﬁrm or reject such nonspeciﬁc interactions of GaTC3-OGDOTA.
The use of a PET tracer has great potential for translational
studies of brain pathologies, but it also brings a number of
experimental diﬃculties. 68Ga has a half-life of 68 min, which
requires rapid use of the tracer after its generation. The
resolution of [68Ga]Ga-TC3-OGDOTA distribution in mouse
tissues is on the millimeter range, making it diﬃcult to isolate
uptake from speciﬁc mouse brain structures. The resolution
limitation prevented the analysis of uptake from regions of
interest such as the ischemic core in the MCAO model and its
peripheral areas. Here, we used a simpliﬁed assignment of
ROIs that allowed us to distinguish injured and uninjured
halves of the brains using a minimal number of animals.
Nevertheless, standardized uptake varied between mice
within each condition, which prohibited distinguishing injured and control brains by absolute uptake values. This
diﬃculty could be related to the fact that the core of the injury
might take up even less [68Ga]Ga-TC3-OGDOTA than
normal tissue due to tissue lysis and may be diﬀerent between
operated animals. Further work to improve the separation of

the ischemia core, penumbra, and uninjured tissue regions
would simplify the analysis of PET kinetics.
While the bifunctionality of [68Ga]Ga-TC3-OGDOTA
allows imaging of subcellular compartments to organs and
tissues, its radioactivity limited our ability to proceed to
ﬂuorescence microscopy immediately after the PET procedure. Indeed, the animals had to be processed in a nonradioactive facility 20 h after the tracer injection, which
might have inﬂuenced its distribution throughout the brain
tissue, particularly, in a fast-developing insult such as stroke.
Of note, in this proof-of-principle study, we did not attempt
codetection of [68Ga]Ga-TC3-OGDOTA by PET and microscopy in the same brain cells, but rather radiolocalization
of the tracer in the apoptosis-aﬀected regions of the brain
and its further ﬂuorescence localization within CC3-positive
brain cells. However, in the future studies, it will be important to shorten the delay between the PET procedure and
extraction of the brain for confocal microscopy.
The current study is mainly exploratory, due to the
novelty of the tracer and unknown amount of apoptotic
neurodegeneration in the disease mouse models used in this
work. Therefore, we did not estimate the sample size needed
prior to starting these experiments, but rather, based on the
obtained results, predicted the necessary sample size for
future studies to achieve power of 0.8. For Patlak analysis, we
obtained a sample size N � 4 for MCAO mice and N � 6 for
all groups of 5xFAD mice, which is slightly lower than the
number of animals used in the current study, except for
5xFAD males. To detect diﬀerences between linear decay
constants in 5xFAD and wild-type mice, N � 3 is needed for
all groups. The only comparison that did not include a large
enough sample based on postexperiment estimates was the
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comparison of MCAO ipsilateral and contralateral sides of
the brain. This comparison was estimated to need N � 16 for
the linear decay approximation analyses and N � 18 for
Patlak analyses. Future improvements in ROI assignment
should help reduce these numbers.
Another limitation of this study is the unknown stability
of [68Ga]Ga-TC3-OGDOTA during the imaging procedure.
Future studies should evaluate the stability of the radiotracer
under various pH conditions and in blood plasma. It has also
been shown that under certain neuropathological conditions, such as AD or stroke, the neurovasculature is aﬀected.
Currently, it is unknown whether neurovasculature changes
could aﬀect the blood-brain barrier penetration of our
tracer. Future studies should directly compare the eﬃciency
of blood-brain barrier crossing of [68Ga]Ga-TC3-OGDOTA
under diﬀerent conditions. An arterial input function was
not used in the current study. It is possible to approximate
the arterial input function given some assumptions, or to
measure it directly. However, the former approach has no
consensus, and the latter approach is challenging for very
small animals (e.g., mice). Finally, a fundamental limitation
of 68Ga is the high positron range, which eﬀectively reduces
resolution compared to 18F. Although micro-PET was used
in the current study, the use of such a system does not
mitigate this speciﬁc limitation. The use of micro-PET/CT in
the future would improve registration of PET images with
images of brain anatomy to study pharmacokinetics in small
regions.
In addition to stroke and AD, there are other neurodegenerative conditions featuring signiﬁcant neuronal loss,
including Parkinson and prion diseases. Further work
employing [68Ga]Ga-TC3-OGDOTA in these disease models
is warranted. While the limited number of mice at speciﬁc
ages in this work did not allow for the analysis of sex-based
diﬀerences, such comparisons are warranted in future studies
to determine whether there are sex-based diﬀerences in apoptosis in this AD mouse model. Another application for
[68Ga]Ga-TC3-OGDOTA could be in the in vivo assessment
of therapeutic eﬃcacy in cancer. Considering possible negative side eﬀects on subjects, Ga-TC3-OGDOTA/[68Ga]GaTC3-OGDOTA did not exert any overt toxicity in neuronal
cultures, nor did it cause observable discomfort/disease in the
injected mice. Nevertheless, a detailed study of its half-life in
mice and possible toxic eﬀects in a second species should be
performed prior to clinical studies.

5. Conclusions
In conclusion, the caspase-3-targeted [68Ga]Ga-TC3OGDOTA designed in the current study accumulates in
neurons expressing increased levels of CC3 indicative of
apoptosis. Ga-TC3-OGDOTA/[68Ga]Ga-TC3-OGDOTA accumulation was observed in vitro in primary neurons using its
ﬂuorescent tag following CPT, OGD, and AβO toxicity.
Furthermore, it was detected in vivo and ex vivo in the brain
in mouse models of cerebral ischemia and Alzheimer’s disease, using 68Ga-PET and CLARITY imaging. This tracer
molecule has many potential applications associated with the
early detection of neurodegenerative conditions including
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Alzheimer’s disease, and in the development of novel therapeutics for cancer.
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Supplementary Materials
Supplementary 1. Supplementary Figure 1. Principle of
[68Ga]Ga-TC3-OGDOTA retention in apoptotic cells and
HPLC veriﬁcation of its purity. (a) Scheme of [68Ga]GaTC3-OGDOTA (top) interaction with healthy (bottom left)
and apoptotic, containing active/cleaved caspase-3 (CC3,
bottom right) cells. (b) HPLC for free Oregon Green conjugate (top), radiolabeled probe 3 (centre), and probe 3
labeled with “cold” nonradioactive Ga3+ (bottom) was done
as described in Methods (Method C).
Supplementary 2. Supplementary Figure 2. Apoptotic
markers in primary neuronal cultures treated with toxic
agents. (a, b) Neuronal cultures were treated with 10 µM
CPT as described in Methods, and immunostained for
cleaved caspase 3 (red) and nuclear marker (DAPI, cyan).
Cultures were imaged using 20x (a) or 63x (b) objective on a
confocal microscope. (c) Neuronal cultures were treated
with OGD for 1 h as described in Methods and immunostained for cleaved caspase 3 (red) and nuclear marker
(Hoechst, blue). Cultures were imaged using 20x objective
on a FV1000 Olympus confocal microscope. (d) Neuronal
cultures were treated with AβOs for 24 h as described in
Methods and immunostained for cleaved caspase 3 (red) and
nuclear marker (Hoechst, blue). Cultures were imaged using
60x objective on a FV1000 Olympus confocal microscope.
Supplementary 3. Supplementary Figure 3. Confocal and
CLARITY imaging of MCAO mouse brains. (a) TTC
staining of MCAO mouse brains reveals variations in the
ischemic injury core size. (b) Sample kinetics for PET imaging of [68Ga]Ga-TC3-OGDOTA injected in a 3-monthold male mouse. SUV was calculated for brain, bladder,
kidney, liver, hip, and left ventricle as PET signal integrated
over the region of interest and normalized by ID/weight (g).
SUV is presented as mean ± SD. (c) Comparison of Oregon
Green imaging (ex505/em525-560) in MCAO mouse brains
injected (left panel) or not (two right panels) with [68Ga]GaTC3-OGDOTA. White arrows point at [68Ga]Ga-TC3OGDOTA-positive cells, wide green arrow—at nonspeciﬁc green glare in MCAO tissue, thin green arrows—at
self-ﬂuorescing blood vessels. (d) Neuronal cultures treated
with OGD and incubated for 7 h under normal conditions
with 1 µM [68Ga]Ga-TC3-OGDOTA were extensively
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washed for 72 h with clearing solution (4% SDS in 200 mM
sodium borate, pH 8.5) at 37 °C or stored at 37 °C without
washing (control). Imaging was performed using an FV1000
confocal microscope equipped with 30x objective. (e)
CLARITY steps: left—2 mm coronal brain sections after 72 h
clearing as described in Methods; right—the same section
after incubation for 2 h in SeeDB mounting medium and
mounting on a slide.
Supplementary 4. Supplementary video 1. 3D reconstruction
of Z-stack confocal images of a 0.7 mm thick coronal section
(cortical area) of MCAO-operated mouse after [68Ga]GaTC3-OGDOTA (Oregon Green � green) injection. Operated
side is on the left in the beginning of the video.
Supplementary 5. Supplementary video 2. 3D reconstruction
of Z-stack confocal images of a 0.7 mm thick coronal section
(midbrain area) of MCAO-operated mouse after [68Ga]GaTC3-OGDOTA (Oregon Green � green) injection. Operated
side is on the left in the beginning of the video.
Supplementary 6. Supplementary video 3. 3D reconstruction
of Z-stack confocal images of a 0.7 mm thick coronal section
(cortical area) of MCAO-operated mouse after [68Ga]GaTC3-OGDOTA injection and immunostaining for CC3
(gold). Operated side is on the left.
Supplementary 7. Supplementary video 4. 3D reconstruction
of Z-stack confocal images of a 0.7 mm thick coronal section
(midbrain area) of MCAO-operated mouse after [68Ga]GaTC3-OGDOTA injection and immunostaining for CC3
(gold). Operated side is on the left in the beginning of the
video.
Supplementary 8. Supplementary video 5. 3D reconstruction
of Z-stack confocal images of 0.2 mm thick coronal sections
of 5xFAD mouse brains (bottom) and its wild-type control
(top) after [68Ga]Ga-TC3-OGDOTA (Oregon Green �
green) injection.
Supplementary 9. Supplementary video 6. 3D reconstruction
of Z-stack confocal images of a 0.2 mm-thick coronal section
(hippocampus area) of 5xFAD mouse brains after [68Ga]GaTC3-OGDOTA (Oregon Green�green) injection.
Supplementary 10. Supplementary video 7. 3D reconstruction of Z-stack confocal images of a half of a 0.2 mm
thick coronal section of 5xFAD mouse brains after [68Ga]
Ga-TC3-OGDOTA (Oregon Green � yellow) injection and
staining with Thioﬂavin S (blue) for amyloid plaques. The
microscope was equipped with a 10x objective lens.
Supplementary 11. Supplementary video 8. 3D reconstruction
of Z-stack confocal images of a 0.4 mm-thick coronal section
(hippocampal area) of 5xFAD mouse brains after [68Ga]GaTC3-OGDOTA (Oregon Green � yellow) injection and
staining with Thioﬂavin S (blue) for amyloid plaques. The
microscope was equipped with a 30x objective lens.
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